Literature DB >> 7612531

First trimester fetal nuchal translucency: problems with screening the general population. 1.

L J Roberts1, S Bewley, A M Mackinson, C H Rodeck.   

Abstract

OBJECTIVE: To evaluate the feasibility of measuring first trimester nuchal translucency in an unselected population, to assess the relationship with gestation and maternal age and to measure reproducibility.
DESIGN: A prospective observational study.
SETTING: University College Hospital, London.
SUBJECTS: One thousand and four women attending for a routine first trimester dating scan between eight and thirteen weeks of gestation. Measurements of nuchal translucency were attempted in 1368 (80.3%) and successful in 1127 (82% of attempts).
RESULTS: Nuchal translucency is most easily measured at 11 weeks of gestation. If a cut-off of > or = 3 mm is used, 6% of unselected fetuses between eight and thirteen weeks of gestation are classified as abnormal. Nuchal translucency increases with gestational but not maternal age. Reproducibility is poor: by repeating measurements with a different operator, the same operator using a different still image, or the same operator using the same still image, 18.8%, 17.5% or 12.4% of nuchal translucency measurements, respectively, change their classification as normal or abnormal.
CONCLUSIONS: If nuchal translucency > or = 3mm were used as an indication for karyotyping, 6% of the normal pregnant population would be screen positive. However, the percentage will vary greatly depending on the gestational age profile of the screened population. The poor reproducibility of nuchal translucency measurement could diminish its usefulness as a screening test for Down's syndrome.

Entities:  

Mesh:

Year:  1995        PMID: 7612531     DOI: 10.1111/j.1471-0528.1995.tb11289.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  9 in total

Review 1.  Recent advances. Obstetrics.

Authors:  P Steer
Journal:  BMJ       Date:  1995-11-04

Review 2.  First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome.

Authors:  S Shiefa; M Amargandhi; J Bhupendra; S Moulali; T Kristine
Journal:  Indian J Clin Biochem       Date:  2012-10-12

Review 3.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 4.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 5.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

6.  Fetal nuchal translucency scan in Nigeria.

Authors:  Olufemi Adebari Oloyede; Mkpe Abbey; Adeniyi Adebowale Oloyede; Onyinye Nwachukwu
Journal:  Pan Afr Med J       Date:  2014-05-18

7.  A prospective study to assess the clinical impact of interobserver reliability of sonographic measurements of fetal nuchal translucency and crown-rump length on combined first-trimester screening.

Authors:  Huseyin Aksoy; Sezin Ozyurt; Ulku Aksoy; Erol Mutlu; Sadan Tutus; Mustafa Alparslan Babayigit; Gokhan Acmaz; Ozge Idem Karadag; Burak Yucel
Journal:  North Clin Istanb       Date:  2015-09-25

Review 8.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

Review 9.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.